EFSA J. 2021 Mar 26;19(3):e06553. doi: 10.2903/j.efsa.2021.6553. eCollection 2021 Mar.
[Table: see text] The general guidance for stakeholders on the evaluation of Article 13(1), 13(5) and 14 health claims was first published in March 2011. Since then, the Panel on Dietetic Products Nutrition and Allergies (NDA) has completed the scientific assessment of Article 13(1) claims except for claims put on hold by the European Commission, and has assessedadditional health claim applications submitted pursuant to Articles 13(5), 14 and also 19. In addition, comments received from stakeholders indicate that general issues that are common to all health claims need to be further clarified and addressed. This guidance document aims to explain the general scientific principles applied by the NDA Panel for the scientific assessmentof all health claims and outlines a series of steps for the compilation of applications. The general guidance document represents the views of the NDA Panel based on the experience gained to date with the scientific assessment of health claims, and it may be further updated, as appropriate, when additional issues are addressed.The document also aims to inform applicants of newprovisionsin the pre-submission phase and in the application procedure set out in the General Food Law, as amended by the Transparency Regulation. These new provisions are applicable to all applications submitted as of 27 March 2021. The version of this guidance published in 2016 remains applicable for applications submitted before 27 March 2021.
[表格:见正文] 利益相关者对第13(1)条、第13(5)条和第14条健康声明评估的一般指南于2011年3月首次发布。自那时以来,营养、新型食品及过敏症专家组(NDA)已完成了对第13(1)条声明的科学评估,但欧洲委员会搁置的声明除外,并已评估了根据第13(5)条、第14条以及第19条提交的其他健康声明申请。此外,从利益相关者收到的评论表明,所有健康声明共有的一般问题需要进一步澄清和解决。本指南文件旨在解释NDA专家组在对所有健康声明进行科学评估时所适用的一般科学原则,并概述编制申请的一系列步骤。该一般指南文件代表了NDA专家组基于迄今在健康声明科学评估中获得的经验所形成的观点,并可能在解决其他问题时酌情进一步更新。本文件还旨在告知申请人《一般食品法》(经《透明度条例》修订)在提交前阶段和申请程序中的新规定。这些新规定适用于2021年3月27日及以后提交的所有申请。2016年发布的本指南版本仍适用于2021年3月27日之前提交的申请。